Skip navigation


Hereditary cancer testing, made accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis.

Empower screens for genes associated with increased risk for common hereditary cancers. Our Empower multi-cancer panels include commonly screened-for genes associated with 12+ types of cancer.

Getting Started with the Empower Hereditary Cancer Test

Inherited mutations can significantly increase lifetime risk for developing cancer1

Inherited mutations can significantly increase lifetime risk for developing cancer

Learn More About Genetic Mutations & Hereditary Cancers

Hereditary Breast and Ovarian Cancer (HBOC) Syndrome

Up to 10% of all breast cancers can be attributed to hereditary causes, the most well known of which is a BRCA1 or 2 mutation. Inherited mutations can increase a woman’s risk for breast cancer to greater than 60%, yet up to 97% of women who carry that risk don’t know it. Patients who know their hereditary or familial cancer risk have better outcomes than those who don’t.1, 2

Learn More: Hereditary Breast Cancer

Amy’s Story

More Informed Treatment with Hereditary Cancer Testing

Listen to an interactive panel discussion between breast cancer patient survivors, previvors and women’s health clinicians.

“Had I known that I carried the BRCA1 mutation when I was first diagnosed, I would have had the opportunity for different treatment options. It’s an important lesson for providers – talk about family cancer history.”

AMY V. – BRCA1 mutation carrier, breast cancer survivor

Lynch Syndrome

As many as 1 in 370 people are Lynch syndrome carriers, yet 95% of them do not know. Lynch syndrome is the most common inherited cause of colon cancer and endometrial cancer. In fact, gynecologic cancer is a hallmark of Lynch syndrome. Lynch syndrome can be identified early to manage cancer risk.3, 4, 5, 6, 7

Learn More: Lynch Syndrome

How to identify and manage hereditary cancer risk

Jennifer’s Story

“I feel like the luckiest person in the world to have this information. I can be a previvor. I can take control of my health now and make sure that I don’t ever have to deal with uterine or colon cancer like every woman in my maternal line has so far.”

JENNIFER PLENT – Lynch syndrome mutation carrier, cancer previvor

How it works


Provider orders an Empower Hereditary Cancer Test.


Patient provides a blood or saliva sample.


Patients review results with their provider within 2 weeks.

Actionable reports guide next steps, including:

  • Detect cancer at its earliest, most treatable stage
  • Identify risk-reducing medications and surgeries
  • Inform surgical and therapeutic decisions following a cancer diagnosis
  • Notify family members to help them proactively manage hereditary cancer risk
Actionable reports guide next steps

Making the difference for families with hereditary cancer

“Our mom isn’t here to walk us through this journey.” Hannah and Katie made proactive health plans together after learning they carry a BRCA1 mutation.

Streamlined family cancer history intake with NEVA

  • Streamlined family cancer history intake with NEVA
  • Providers have a single view of patient risk assessment details and all Natera test orders

Is Empower right for you? Contact us.


1Cancer risk estimates for a positive result are typically based on individuals with a family or personal history of cancer. NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic v2.2021

2Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ. Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015. J Natl Cancer Inst. 2019 Aug 1;111(8):795-802. doi: 10.1093/jnci/djz008. PMID: 30753636; PMCID: PMC6695306.

3Hampel H, de la Chapelle A. “How do we approach the goal of identifying everybody with Lynch syndrome?” Familial Cancer, Jun. 2013, editorial board. “Lynch Syndrome.” Cancer.Net, 11 Aug. 2021,

5Lowry, Blue Ribbon Panel Report. 2016.

6Surveillance, Epidemiology and End Results (SEER) Program (

7Rubenstein JH et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7.f